Roivant Sciences revenue and financials
$35.53Change from previous close: −0.70%Absolute change: −$0.25
In the fiscal year ended March 2026, Roivant Sciences reported revenue of $8.26M (−71.57% year over year). The net loss was $299.77M.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −71.57%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3,629.2%
- FY to Mar 2025: -592.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -271 | -164 | -196 | -186 | -204 | -173 | -207 | -267 | -193 | -108 | -210 | -250 |
| Depreciation and amortization | 0.6 | 0.6 | 0.7 | 0.9 | 1.1 | 8.2 | 1.9 | 1.9 | 2.0 | 13.8 | 2.5 | 5.8 |
| Capital expenditure | -0.4 | -1.3 | 4.9 | -7.8 | -4.0 | -0.8 | -1.8 | -1.0 | -1.0 | -0.3 | -0.4 | -0.4 |
| Investing cash flow | 281 | 173 | 109 | 120 | -1,086 | 1,074 | 454 | -3,294 | -1.0 | 6.9 | 5,233 | 0.1 |
| Financing cash flow | -182 | -68.8 | 328 | 62.6 | -188 | -177 | -273 | -109 | -661 | -32.6 | 237 | 7.5 |
| Share repurchases | -258 | -119 | -23.9 | -6.5 | -218 | -303 | -252 | -115 | -661 | -28.6 | -3.3 | -5.7 |
| Debt repaid | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -49.1 | -1.8 | -1.8 | -7.7 | -7.7 | -7.8 |
| Effect of exchange rates | 0.3 | 1.3 | 0.4 | 1.2 | 0.8 | -0.5 | -1.1 | 5.0 | -2.7 | -0.9 | 3.0 | -0.1 |
| Net change in cash | -170 | -57.8 | 242 | -1.4 | -1,477 | 724 | -27.2 | -3,664 | -857 | -135 | 5,262 | -242 |
| Free cash flow | -271 | -165 | -192 | -194 | -208 | -173 | -209 | -268 | -194 | -109 | -211 | -250 |
| Levered free cash flow | -169 | -772 | -88.8 | -101 | -132 | -15.5 | -304 | 124 | -227 | -85.4 | -72.0 | -108 |